~~<i id='63A183B892'><strike id='63A183B892'><tt id='63A183B892'><pre id='63A183B892'></pre></tt></strike></i>~~

Home» comprehensive» leisure time

leisure time

author：focus 2025-09-29 12:07:15 Page View：963

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Biogen Aduhelm mess could happen again
Next article： Jerome Adams on the need for new antivirals for Covid

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Unique patient identifier: Experts argue the benefits, pitfalls

Therehasbeenlong-standingdebateintheUSoverwhethertoimplementauniquepatientidentifiersystem.EvanVucci

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

RedCrossvolunteersdelivermealsattheRollingForkMotel,wheredisplacedfamiliesarelivingaftertheirhomeswe